‘Pharma study to help CCI take steps to raise drug affordability’
The Hindu
Currently, competition is based on brands, not price: Gupta
Fair trade regulator CCI will identify measures to enhance competition in the country’s pharmaceutical sector for ensuring affordability of drugs after analysing findings of its market study, which is likely to be completed within a month, according to its chief Ashok Kumar Gupta.
The Competition Commission of India (CCI), which keeps a tab on unfair, initiated the study after observing issues such as lack of “effective consumer choice”.
“Currently, it appears that, when it comes to medicines, competition is primarily on the basis of brands and not prices. The study will identify measures to increase competition for ensuring affordability of drugs,” the CCI chairperson said. Market studies had been initiated in pharmaceuticals and telecom, given their significance in the “new COVID-19-induced socio-economic milieu”.

Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.












